Chimeric RNAs as Novel Neoantigens for Extracellular Vesicles-Based Vaccines Against Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Tumor vaccines often rely on neoantigens derived from mutations, which are scarce in some cancers.
• This limitation hinders the development of effective immunotherapies for specific tumor types.

Purpose of the Study:

• To investigate tumor-specific chimeric RNAs as an alternative source of neoantigens.
• To develop a novel extracellular vesicle (EV)-based vaccine strategy using chimeric RNAs for cancer therapy.

Main Methods:

• Utilized flow cytometry and cell counting kit-8 (CCK-8) assays to identify and validate chimeric RNAs as neoantigens.
• Employed mouse tumorigenesis models to test the efficacy of EV-based chimeric RNA vaccines.

Main Results:

• Demonstrated that aberrantly spliced tumor-specific chimeric RNAs, such as ASTN2-PAPPA antisense chimeric RNA (A-PaschiRNA), can function as neoantigens.
• Successfully developed and tested extracellular vesicle (EV)-based vaccines loaded with chimeric RNAs in preclinical models.

Conclusions:

• Tumor-specific chimeric RNAs represent a viable alternative to mutation-based neoantigens for cancer vaccine development.
• Extracellular vesicle (EV)-based chimeric RNA vaccines show promise as a therapeutic strategy for esophageal squamous cell carcinoma.